Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Riho Klement"'
Autor:
Dorte Vistisen, Bendix Carstensen, Patorno Elisabetta, Stefanie Lanzinger, Elise Chia-Hui Tan, Daisuke Yabe, Dae Jung Kim, Wayne H.-H. Sheu, Cheli Melzer-Cohen, Reinhard W. Holl, Júlio Núñez, Kyoung Hwa Ha, Sigrun Halvorsen, Gisle Langslet, Avraham Karasik, Thomas Nyström, Leo Niskanen, Sonia Guleria, Riho Klement, Marc Carrasco, Johannes Foersch, Christina Shay, Lisette Koeneman, Fabian Hoti, Soulmaz Fazeli Farsani, Kamlesh Khunti, Francesco Zaccardi, Anuradhaa Subramanian, Krishnarajah Nirantharakumar, EMPRISE EU, East Asia Study Group
Publikováno v:
Cardiovascular Diabetology, Vol 22, Iss 1, Pp 1-12 (2023)
Abstract Background Studies that have reported lower risk for cardiovascular outcomes in users of Sodium–Glucose Cotransporter-2 Inhibitors (SGLT-2i) are limited by residual cofounding and lack of information on prior cardiovascular disease (CVD).
Externí odkaz:
https://doaj.org/article/a2bb1c7f2f2448239e817140320a7e7e
Autor:
Wayne H‐H Sheu, Yutaka Seino, Elise Chia‐Hui Tan, Daisuke Yabe, Kyoung Hwa Ha, Masaomi Nangaku, Wook‐Jin Chung, Koichi Node, Atsutaka Yasui, Wei‐Yu Lei, Sunwoo Lee, Anastasia Ustyugova, Riho Klement, Anouk Deruaz‐Luyet, Moe H Kyaw, Dae Jung Kim, the EMPRISE East Asia study group
Publikováno v:
Journal of Diabetes Investigation, Vol 13, Iss 5, Pp 810-821 (2022)
ABSTRACT Aims/Introduction We investigated the utilization of healthcare resources in patients with type 2 diabetes treated with empagliflozin, a sodium‐glucose co‐transporter‐2 (SGLT2) inhibitor, versus dipeptidyl peptidase‐4 (DPP‐4) inhib
Externí odkaz:
https://doaj.org/article/7f7c784bc36e45fdb973717cf420b9e6
Autor:
Yutaka Seino, Dae Jung Kim, Daisuke Yabe, Elise Chia‐Hui Tan, Wook‐Jin Chung, Kyoung Hwa Ha, Masaomi Nangaku, Koichi Node, Riho Klement, Atsutaka Yasui, Wei‐Yu Lei, Sunwoo Lee, Moe H. Kyaw, Anouk Deruaz‐Luyet, Kimberly G. Brodovicz, Wayne H.‐H. Sheu, the EMPRISE East Asia study group
Publikováno v:
Endocrinology, Diabetes & Metabolism, Vol 4, Iss 1, Pp n/a-n/a (2021)
Abstract Aim To evaluate the effectiveness of empagliflozin in clinical practice in East Asia in the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) East Asia study. Materials and methods Data were obtained from the Medical Data Vision d
Externí odkaz:
https://doaj.org/article/b9d082c7bc384035bc5f92b568082777
Autor:
Avraham Karasik, Stefanie Lanzinger, Elise Chia-Hui Tan, Daisuke Yabe, Dae Jung Kim, Wayne H-H Sheu, Cheli Melzer-Cohen, Reinhard W. Holl, Kyoung Hwa Ha, Kamlesh Khunti, Francesco Zaccardi, Anuradhaa Subramanian, Krishnarajah Nirantharakumar, Thomas Nyström, Leo Niskanen, Majken Linnemann Jensen, Fabian Hoti, Riho Klement, Anouk Déruaz-Luyet, Moe H. Kyaw, Lisette Koeneman, Dorte Vistisen, Bendix Carstensen, Sigrun Halvorsen, Gisle Langslet, Soulmaz Fazeli Farsani, Elisabetta Patorno, Júlio Núñez
Publikováno v:
Karasik, A, Lanzinger, S, Chia-Hui Tan, E, Yabe, D, Kim, D J, Sheu, W H H, Melzer-Cohen, C, Holl, R W, Ha, K H, Khunti, K, Zaccardi, F, Subramanian, A, Nirantharakumar, K, Nyström, T, Niskanen, L, Linnemann Jensen, M, Hoti, F, Klement, R, Déruaz-Luyet, A, Kyaw, M H, Koeneman, L, Vistisen, D, Carstensen, B, Halvorsen, S, Langslet, G, Fazeli Farsani, S, Patorno, E, Núñez, J & EMPRISE Europe and Asia Study Group 2023, ' Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia : Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study ', Diabetes and Metabolism, vol. 49, no. 2, 101418 . https://doi.org/10.1016/j.diabet.2022.101418
BackgroundContinued expansion of indications for sodium-glucose cotransporter-2 inhibitors increases importance of evaluating cardiovascular and kidney efficacy and safety of empagliflozin in patients with type 2 diabetes compared to similar therapie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1de9ce973039544fcdaf3682da4ff82a
http://hdl.handle.net/10852/102728
http://hdl.handle.net/10852/102728
Autor:
null Thomas Nyström, null Emilie Toresson Grip, null Joel Gunnarsson, null Paula Casajust, null Kristina Karlsdotter, null Josefin Skogsberg, null Anastasia Ustyugova, null Moe H. Kyaw, null Maria Lajer, null Gitte Mateusen, null Lisette Koeneman, null Neus Valveny, null Emma Söreskog, null Riho Klement, null Fabian Hoti, null EMPRISE Study Group
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8c902b3b3bbd218b6f51e1bd1d012824
https://doi.org/10.1111/dom.14870/v2/response1
https://doi.org/10.1111/dom.14870/v2/response1
Autor:
Atsutaka Yasui, Yutaka Seino, Daisuke Yabe, Masaomi Nangaku, Kyoung Hwa Ha, Koichi Node, Moe H. Kyaw, Dae Jung Kim, Wayne H-H Sheu, Anastasia Ustyugova, Elise Chia-Hui Tan, Sunwoo Lee, Wei-Yu Lei, Anouk Deruaz-Luyet, Wook-Jin Chung, Riho Klement
Publikováno v:
Journal of diabetes investigation. 13(5)
AIMS/INTRODUCTION We investigated healthcare resources utilization in type 2 diabetes (T2D) patients treated with empagliflozin, a sodium-glucose co-transporter-2 inhibitor, versus dipeptidyl peptidase-4 (DPP-4) inhibitors in clinical practice in Jap
Autor:
Maria Pilar Escribano-Subias, Sean P. Gaine, Audrey Muller, Riho Klement, Tobias Lange, Stefan Söderberg
Publikováno v:
Journal of the American College of Cardiology. 79:1669
Autor:
Katja Marja Hakkarainen, Rosa Juuti, Sarah Burkill, Yvonne Geissbühler, Meritxell Sabidó, Catrinel Popescu, Kiliana Suzart-Woischnik, Jan Hillert, Miia Artama, Auli Verkkoniemi-Ahola, Kjell-Morten Myhr, Juha Mehtälä, Shahram Bahmanyar, Scott Montgomery, Pasi Korhonen, Alessandra Adamo, Eva-Maria Wicklein, Metin Akbaba, Gustavo Borghesi, Evra Köfüncü, Nicholas Everage, Avni Pandhi, Maria Naylor, Anh Ly, Dominic Jack, Milorad Todorovic, Delphine Issard, Alexandra Macklin, Paola Primatesta, Richard Weitzman, Riho Klement, Minna Vehkala, Pia Vattulainen, Marta Korjagina, Hanna Gyllensten
Publikováno v:
Therapeutic Advances in Neurological Disorders
Therapeutic Advances in Neurological Disorders (TAND)
Therapeutic Advances in Neurological Disorders, Vol 13 (2020)
Therapeutic Advances in Neurological Disorders (TAND)
Therapeutic Advances in Neurological Disorders, Vol 13 (2020)
Background Our aim was to estimate and compare the prevalence of adverse pregnancy outcomes among pregnant women with multiple sclerosis (MS) exposed to interferon beta (IFNB) and among women with MS unexposed to any MS disease-modifying drug (MSDMD)
Autor:
Atsutaka Yasui, Riho Klement, Dae Jung Kim, Wayne H-H Sheu, Daisuke Yabe, Masaomi Nangaku, Koichi Node, Wei-Yu Lei, Anouk Deruaz-Luyet, Kyoung Hwa Ha, Moe H. Kyaw, Kimberly G. Brodovicz, Wook-Jin Chung, Sunwoo Lee, Elise Chia-Hui Tan, Yutaka Seino
Publikováno v:
Endocrinology, Diabetes & Metabolism
Endocrinology, Diabetes & Metabolism, Vol 4, Iss 1, Pp n/a-n/a (2021)
Endocrinology, Diabetes & Metabolism, Vol 4, Iss 1, Pp n/a-n/a (2021)
Aim To evaluate the effectiveness of empagliflozin in clinical practice in East Asia in the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) East Asia study. Materials and methods Data were obtained from the Medical Data Vision database (
Autor:
Wei-Yu Lei, Yutaka Seino, Daisuke Yabe, Anouk Deruaz-Luyet, Wook-Jin Chung, Dae Jung Kim, Wayne H-H Sheu, Elise Tan, Yusuke Taneda, Kyoung Hwa Ha, Moe H. Kyaw, Anastasia Ustyugova, Riho Klement
Publikováno v:
Journal of the American College of Cardiology. 77:1470